Institute of Applied Mechanics, National Taiwan University, 1 Roosevelt Road, Sec. 4, Taipei 106319, Taiwan.
Reliance Biosciences, Inc., New Taipei City 231023, Taiwan.
ACS Appl Mater Interfaces. 2024 Aug 28;16(34):44386-44398. doi: 10.1021/acsami.4c03869. Epub 2024 Aug 16.
Extracellular vesicles (EVs) are present in blood at much lower concentrations (5-6 orders of magnitude) compared to lipoprotein particles (LP). Because LP and EV overlap in size and density, isolating high-purity EVs is a significant challenge. While the current two-step sequential EV isolation process using size-expression chromatography (SEC) followed by a density gradient (DG) achieves high purity, the time-consuming ultracentrifugation (UC) step in DG hinders workflow efficiency. This paper introduces an optimized magnetic bead reagent, LipoMin, functionalized with glycosaminoglycans (GAGs), as a rapid alternative for LP removal during the second-step process in about 10 minutes. We evaluated LipoMin's efficacy on two sample types: (a) EV fractions isolated by size exclusion chromatography (SEC + LipoMin) and (b) the pellet obtained from ultracentrifugation (UC + LipoMin). The workflow is remarkably simple, involving a 10 min incubation with LipoMin followed by magnetic separation of the LP-depleted EV-containing supernatant. Results from enzyme-linked immunosorbent assay (ELISA) revealed that LipoMin removes 98.2% ApoB from SEC EV fractions, comparable to the LP removal ability of DG in the SEC + DG two-step process. Importantly, the EV yield (CD81 ELISA) remained at 93.0% and Western blot analysis confirmed that key EV markers, flotillin and CD81, were not compromised. Recombinant EV (rEV), an EV reference standard, was spiked into SEC EV fractions and recovered 89% of CD81 protein. For UC + LipoMin, ApoA1 decreased by 76.5% while retaining 90.7% of CD81. Notably, both colorectal cancer (CRC) and Alzheimer's disease (AD) samples processed by SEC + LipoMin and UC + LipoMin displayed clear expression of relevant EV and clinical markers. With a 10 min workflow (resulting in a 96% time saving compared to the traditional method), the LipoMin reagent offers a rapid and efficient alternative to DG for LP depletion, paving the way for a streamlined SEC + LipoMin two-step EV isolation process.
细胞外囊泡 (EVs) 在血液中的浓度比脂蛋白颗粒 (LP) 低得多 (相差 5-6 个数量级)。由于 LP 和 EV 在大小和密度上有重叠,因此分离高纯度的 EV 是一个巨大的挑战。虽然目前使用尺寸表达色谱 (SEC) followed by 密度梯度 (DG) 的两步连续 EV 分离过程可实现高纯度,但 DG 中耗时的超速离心 (UC) 步骤阻碍了工作流程效率。本文介绍了一种优化的磁性珠试剂 LipoMin,它通过糖胺聚糖 (GAGs) 功能化,可作为第二步过程中去除 LP 的快速替代物,在大约 10 分钟内完成。我们评估了 LipoMin 在两种样品类型上的效果:(a) 通过尺寸排阻色谱 (SEC + LipoMin) 分离的 EV 级分,以及 (b) 超速离心 (UC + LipoMin) 获得的沉淀。该工作流程非常简单,涉及与 LipoMin 孵育 10 分钟,然后通过磁性分离 LP 耗尽的含 EV 的上清液。酶联免疫吸附测定 (ELISA) 的结果表明,LipoMin 可从 SEC EV 级分中去除 98.2%的 ApoB,与 SEC + DG 两步过程中 DG 去除 LP 的能力相当。重要的是,EV 产量 (CD81 ELISA) 保持在 93.0%,Western blot 分析证实关键的 EV 标志物 flotillin 和 CD81 未受影响。重组 EV (rEV),一种 EV 参考标准,被添加到 SEC EV 级分中,回收了 89%的 CD81 蛋白。对于 UC + LipoMin,ApoA1 降低了 76.5%,而保留了 90.7%的 CD81。值得注意的是,经过 SEC + LipoMin 和 UC + LipoMin 处理的结直肠癌 (CRC) 和阿尔茨海默病 (AD) 样本均清晰地表达了相关的 EV 和临床标志物。LipoMin 试剂的工作流程仅需 10 分钟 (与传统方法相比节省了 96%的时间),为 DG 去除 LP 提供了一种快速有效的替代方法,为简化的 SEC + LipoMin 两步 EV 分离过程铺平了道路。